P/E ratio for Ampio Pharmaceuticals (AMPE)
P/E ratio as of May 2024 (TTM): -0.0160
According to Ampio Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0160101. At the end of 2022 the company had a P/E ratio of -0.0121.
P/E ratio history for Ampio Pharmaceuticals from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0121 | -97.46% |
| 2021 | -0.4785 | -57.27% |
| 2020 | -1.12 | 271.98% |
| 2019 | -0.3010 | -693.54% |
| 2018 | 0.0507 | -104.05% |
| 2017 | -1.25 | 743.22% |
| 2016 | -0.1485 | -63.51% |
| 2015 | -0.4070 | 39.89% |
| 2014 | -0.2909 | -63.36% |
| 2013 | -0.7940 | 8.37% |
| 2012 | -0.7327 | 135.75% |
| 2011 | -0.3108 | -14.93% |
| 2010 | -0.3653 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -66,581.16% | 🇺🇸 USA |
 Pfizer PFE | 14.9 | -93,119.41% | 🇺🇸 USA |
 Abbott Laboratories ABT | 35.6 | -222,690.11% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 25.1 | -156,854.80% | 🇺🇸 USA |
 Rigel Pharmaceuticals RIGL | -5.23 | 32,549.83% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Aerie Pharmaceuticals AERI | -20.3 | 126,902.95% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.